Loading people...
Bard Geesaman primarily invests in the biotechnology and life sciences sectors. His focus areas include novel drug discovery, therapeutic development, and advanced therapeutic modalities, often involving the creation of new companies from scientific breakthroughs.
Bard Geesaman works as a Managing Partner at MPM Capital, a prominent venture capital firm with offices in Boston and San Francisco, dedicated to investing in and building life science companies.
Bard Geesaman stands as a distinguished Managing Partner at MPM Capital, a premier venture capital firm renowned for its pioneering investments in the life sciences sector. At MPM Capital, Mr. Geesaman plays a critical role in the firm's strategy of identifying, founding, and building transformative biotechnology companies from inception. His leadership is instrumental in guiding investments towards innovative therapeutic platforms and drug discovery initiatives that promise to address significant unmet medical needs.
Mr. Geesaman's investment focus is deeply rooted in the biotechnology landscape, encompassing a broad spectrum of areas from novel drug discovery and development to advanced therapeutic modalities. He is particularly adept at recognizing early-stage scientific breakthroughs with the potential to evolve into robust clinical pipelines. His work at MPM Capital often involves a hands-on approach, collaborating closely with scientific founders and management teams to translate cutting-edge research into viable companies capable of delivering life-changing medicines.
Prior to his tenure as a Managing Partner at MPM Capital, Bard Geesaman cultivated an impressive career marked by significant contributions across both venture capital and operational roles within the biotech industry. He earned his Master of Business Administration from Harvard Business School and holds a Bachelor of Arts from Yale University, providing him with a strong foundation in both business acumen and scientific understanding. This dual perspective has been invaluable in his ability to evaluate complex scientific propositions and guide their commercial development. His extensive background has equipped him with a unique insight into the challenges and opportunities inherent in bringing novel therapies to market.
Throughout his career, Mr. Geesaman has been instrumental in the creation and growth of numerous successful biotechnology companies. His notable investments and company-building efforts include his involvement with Orna Therapeutics, a leader in circular RNA technology; ReNAgade Therapeutics, focused on RNA medicines; and ElevateBio, a company dedicated to cell and gene therapy manufacturing and development. He also played a key role in Cullinan Oncology, a company developing targeted oncology treatments, and TCR2 Therapeutics, which was acquired by Adaptimmune, showcasing his ability to identify and nurture companies through successful exits. These examples underscore his strategic vision and commitment to fostering innovation that translates into tangible patient benefits.
Bard Geesaman's dedication to advancing medical science through strategic investment and company building has solidified his reputation as a key figure in the biotechnology venture capital community. His work at MPM Capital continues to drive the development of next-generation therapies, making a profound impact on the future of healthcare.
Bard Geesaman is a Managing Partner at MPM Capital, a life sciences venture capital firm based in the Greater Boston Area. He holds a Doctor of Medicine from Harvard Medical School, a doctorate in Systems Neuroscience from the Massachusetts Institute of Technology, and a Bachelor of Science degree from the University of California, Berkeley. Prior to his current tenure at the rebranded MPM BioImpact, Geesaman served as Vice President of Medical Development at Elan Pharmaceuticals and co-founded biotechnology companies including Chiasma and Solasia Pharma. As an investor, he has directed capital into oncology and therapeutics startups, serving on the boards of iOmx Therapeutics, CODA Biotherapeutics, and TriNetX before its 2020 acquisition by Thoma Bravo. His current focus centers on biotechnology company creation and portfolio management at the intersection of computational biology and digital health.
